IP Library › Granted Patent US 11,781,110
Granted Patent B2
US 11,781,110 · App. 16/096,756 · Granted Oct 10, 2023

Induction of corneal endothelial cells

Inventors: Jiagang Zhao (San Diego, CA); Natalie Afshari (La Jolla, CA)
Assignee: The Regents of the University of California
C12N5/0621A61K35/30A61P27/02C12N5/0037C12N5/0606C12N5/0623C12N5/0696G01N33/5064C12N2500/99C12N2501/15C12N2501/155C12N2501/415C12N2501/727C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,781,110
App. No.
16/096,756
Granted
Oct 10, 2023
Kind
B2
Abstract

Compositions and methods for producing major ocular cell types, including retinal ganglion cells, photoreceptors, retinal pigmented epithelium and corneal endothelial cells, from human pluripotent stem cells under defined culture conditions are provided.

Claims (12)

1. A method of culturing corneal endothelial cells (CECs) in vitro comprising:

a. providing a culture of pluripotent stem cells (PSCs),

b. culturing the PSCs with a culture medium containing WNT pathway signaling inhibitor, a BMP pathway signaling inhibitor, and a TGF-β pathway signaling inhibitor for a time period sufficient to produce a culture of eye field stem cells (EFSCs), wherein the culture of EFSCs comprises 70% or more EFSCs,

c. removing EFSC medium and replacing with a culture medium that lacks the WNT pathway signaling inhibitor and promoting WNT signaling in the EFSCs by removal of EFSC media from the EFSCs to produce a culture of ocular neural crest stem cells (NCSCs), and then

d. changing the culture medium of the NCSCs to one that includes the TGF-β pathway signaling inhibitor and a ROCK signaling inhibitor suppressing TGF-β pathway signaling and ROCK signaling in the culture of NCSCs, thereby producing a culture of culturing CECs;

wherein the WNT pathway signaling inhibitor is IWP2, the BMP pathway signaling inhibitor is LDN193189, and the TGF-β pathway signaling inhibitor is SB431542.

2. The method of claim 1 , wherein the step of suppressing TGFβ and ROCK signaling is conducted in a feeder-free and serum-free defined media by applying a small molecule differentiator to the culture.

3. The method of claim 2 , wherein the small molecule differentiator comprises a ROCK inhibitor and a TGFβ inhibitor.

4. The method of claim 3 , wherein the ROCK inhibitor is H-1125 or Y27632, and wherein the TGFβ inhibitor is SB431542.

5. The method of claim 1 , wherein the CEC culture is expanded into a sheet of cells.

6. The method of claim 1 , wherein the majority of NCSCs express neural crest markers p75NTR and HNK-1.

7. The method of claim 1 , wherein the majority of EFSCs express markers PAX6 and LHX2.

Continuity (2)
Provisional Application 62329467 · Apr 29, 2016
Related Publication 20190119633A1 · Apr 25, 2019